Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy
- 14 September 2016
- journal article
- research article
- Published by Springer Nature in Archives of Toxicology
- Vol. 91 (4) , 1871-1890
Abstract
Mitoxantrone (MTX) is an antineoplastic agent used to treat several types of cancers and on multiple sclerosis, which shows a high incidence of cardiotoxicity. Still, the underlying mechanisms of MTX cardiotoxicity are poorly understood and the potential toxicity of its metabolites scarcely investigated. Therefore, this work aimed to synthesize the MTX-naphthoquinoxaline metabolite (NAPHT) and to compare its cytotoxicity to the parent compound in 7-day differentiated H9c2 cells using pharmacological relevant concentrations (0.01–5 µM). MTX was more toxic in equivalent concentrations in all cytotoxicity tests performed [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction, neutral red uptake, and lactate dehydrogenase release assays] and times tested (24 and 48 h). Both MTX and NAPHT significantly decreased mitochondrial membrane potential in 7-day differentiated H9c2 cells after a 12-h incubation. However, energetic pathways were affected in a different manner after MTX or NAPHT incubation. ATP increased and lactate levels decreased after a 24-h incubation with MTX, whereas for the same incubation time and concentrations, NAPHT did not cause any significant effect. The increased activity of ATP synthase seems responsible for MTX-induced increases in ATP levels, as oligomycin (an inhibitor of ATP synthase) abrogated this effect on 5 µM MTX-incubated cells. 3-Methyladenine (an autophagy inhibitor) was the only molecule to give a partial protection against the cytotoxicity produced by MTX or NAPHT. To the best of our knowledge, this was the first broad study on NAPHT cardiotoxicity, and it revealed that the parent drug, MTX, caused a higher disruption in the energetic pathways in a cardiac model in vitro, whereas autophagy is involved in the toxicity of both compounds. In conclusion, NAPHT is claimed to largely contribute to MTX-anticancer properties; therefore, this metabolite should be regarded as a good option for a safer anticancer therapy since it is less cardiotoxic than MTX.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (SFRH/BPD/63746/2009, SFRH/BPD/110001/2015, PTDC/DTP-FTO/1489/2014)
This publication has 44 references indexed in Scilit:
- Differential Effects of Methyl-4-Phenylpyridinium Ion, Rotenone, and Paraquat on Differentiated SH-SY5Y CellsJournal of Toxicology, 2013
- Lysosomotropic Properties of Weakly Basic Anticancer Agents Promote Cancer Cell Selectivity In VitroPLOS ONE, 2012
- A Cardiac-Specific Robotized Cellular Assay Identified Families of Human Ligands as Inducers of PGC-1α Expression and Mitochondrial BiogenesisPLOS ONE, 2012
- Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidaseBiochimie, 2011
- Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings2010
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI: Journal of the National Cancer Institute, 2010
- Mechanisms of Amine Accumulation in, and Egress from, LysosomesBioanalysis, 2009
- Pharmacokinetics and Metabolism of MitoxantroneClinical Pharmacokinetics, 1990
- Mitoxantrone in advanced breast cancer—a phase II study with special attention to cardiotoxicityEuropean Journal of Cancer and Clinical Oncology, 1984
- Properties of a clonal muscle cell line from rat heartExperimental Cell Research, 1976